Gillim-Ross Laura, Subbarao Kanta
Laboratory of Infectious Diseases, National Insitute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Clin Microbiol Rev. 2006 Oct;19(4):614-36. doi: 10.1128/CMR.00005-06.
The current threat of avian influenza to the human population, the potential for the reemergence of severe acute respiratory syndrome (SARS)-associated coronavirus, and the identification of multiple novel respiratory viruses underline the necessity for the development of therapeutic and preventive strategies to combat viral infection. Vaccine development is a key component in the prevention of widespread viral infection and in the reduction of morbidity and mortality associated with many viral infections. In this review we describe the different approaches currently being evaluated in the development of vaccines against SARS-associated coronavirus and avian influenza viruses and also highlight the many obstacles encountered in the development of these vaccines. Lessons learned from current vaccine studies, coupled with our increasing knowledge of the host and viral factors involved in viral pathogenesis, will help to increase the speed with which efficacious vaccines targeting newly emerging viral pathogens can be developed.
目前禽流感对人类构成的威胁、严重急性呼吸综合征(SARS)相关冠状病毒重新出现的可能性以及多种新型呼吸道病毒的发现,都凸显了制定治疗和预防策略以对抗病毒感染的必要性。疫苗研发是预防病毒广泛传播以及降低与许多病毒感染相关的发病率和死亡率的关键组成部分。在这篇综述中,我们描述了目前在研发针对SARS相关冠状病毒和禽流感病毒疫苗过程中正在评估的不同方法,同时也强调了这些疫苗研发过程中遇到的诸多障碍。从当前疫苗研究中吸取的经验教训,再加上我们对病毒发病机制中涉及的宿主和病毒因素的了解不断增加,将有助于提高研发针对新出现病毒病原体的有效疫苗的速度。